Business
RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled by the RenovoCath® Device Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026 Ended First Quarter with $12.4 million in cash, Sufficient to Fund Operations into at Least the Second Half of 2027 Management to Host Conference Call Today a
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KH8PPWGWgkhj4V41vXuuLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KH8PPWGWgkhj4V41vXuuLA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue","length":75,"tagName":"p"},{"type":"text","content":"Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP™ Therapy Platform Enabled by the RenovoCath® Device","length":169,"tagName":"p"},{"type":"text","content":"Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026 ","length":95,"tagName":"p"},{"type":"text","content":"Ended First Quarter with $12.4 million in cash, Sufficient to Fund Operations into at Least the Second Half of 2027","length":115,"tagName":"p"},{"type":"text","content":"Management to Host Conference Call Today at 4:30 P.M. ET","length":56,"tagName":"p"},{"type":"text","content":"MOUNTAIN VIEW, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its financial results for the first quarter ended March 31, 2026, and is providing shareholders with a business update.","length":405,"tagName":"p"},{"type":"text","content":"“We made important strides in the first quarter of 2026 with strong commercial adoption of the TAMP platform enabled by RenovoCath, resulting in record quarterly revenue exceeding 50% of the revenue we generated in all of 2025,” said Shaun Bagai, Chief Executive Officer of RenovoRx. “We generated Q1 revenue of $563,000, an increase of 136% compared to the fourth quarter of 2025, mainly driven...